Disseminated herpes simplex virus type 1 treated with ixekizumab in a patient with erythrodermic psoriasis: A case report

Figure 1  Early erythrodermic psoriasis with approximately 75% body surface area involvement during the first hospitalization, prior to intensive care admission.

Figure 2  Disseminated cutaneous herpes simplex virus type-1 eruption arising during the second intensive care unit admission, approximately one week after initiation of ixekizumab.

Figure 3  Marked clinical improvement at six-week follow-up, with resolution of widespread erythema and palmoplantar scaling after antiviral therapy and reintroduction of ixekizumab.